- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04304352
Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients (VEX)
A Phase II Study of Metronomic Oral Chemotherapy With Cyclophosphamide Plus Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
This is a phase II study assessing the activity and safety of metronomic chemotherapy with cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four different cohort of patients:
- Untreated (naïve) patients with endocrine responsive disease
- Pretreated patients with endocrine responsive disease
- Untreated (naïve) patients with triple negative disease
- Pretreated patients with triple negative disease The primary endpoint will be the progression-free survival
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an institutional, monocentric, open-label, phase II study of oral "metronomic" Vinorelbine plus Capecitabine and Cyclophosphamide (VEX) in patients with advanced breast cancer .
Patients will receive the combination regimen as follow:
Cyclophosphamide 50 mg daily Capecitabine 500 mg, thrice daily Vinorelbine 40 mg orally thrice a week
Four independent cohorts of patients will be evaluated in the study:
- Untreated (naïve) patients with endocrine responsive disease
- Pretreated patients with endocrine responsive disease
- Untreated (naïve) patients with triple negative disease
- Pretreated patients with triple negative disease Combination will be administered until disease progression or unacceptable toxicity.
The primary endpoint will be to assess the Time to progression (TTP) of VEX combination in the four different cohorts
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Emilia Montagna, MD
- Phone Number: +390257489243
- Email: emilia.montagna@ieo.it
Study Contact Backup
- Name: Claudia A Sangalli
- Phone Number: +390257489840
- Email: claudia.sangalli@ieo.it
Study Locations
-
-
-
Milan, Italy
- Recruiting
- European Institute of Oncology
-
Contact:
- Emilia Montagna, MD
- Phone Number: 243 +390257489
- Email: emilia.montagna@ieo.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pre- or post-menopausal women (age ≥18 years) with histologically or cytologically (cell block) proven, locally advanced (inoperable) or metastatic breast carcinoma. Immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR) according to European Institute of Oncology guidelines is mandatory.
- Patients with HER2 overexpressed tumors, are eligible if they had received previous trastuzumab therapy for advanced disease, and/or a treatment with anti HER2 targeted therapy.
Patients fulfilling one of the following criteria:
- Patients with measurable disease as per RECIST 1.1 criteria. This is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 20 mm with conventional techniques or as 10 mm with spiral CT scan
- Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST 1.1 criteria. Bone lesions must be evaluable by plain CT or MRI. Patients with lesions identified only on radionucleotide bone scan are not eligible.
- Patients may have received any primary and/or adjuvant therapies, as any previous lines of chemotherapy and endocrine therapy for advanced disease. Patients may have received metronomic capecitabine, methotrexate and cyclophosphamide in adjuvant setting at least 12 months before study entry
- Previous treatment with capecitabine, cyclophosphamide and vinorelbine not in metronomic schedule for advanced disease is allowed, provided that the patient has progressive disease at study entry and the patients should not be defined as "refractory" to treatments (Pathological Response or Complete Response or Stable Disease > 6 months).
- Patients may have had previous hormonal therapy as treatment of metastatic disease provided that the patient has progressive disease at study entry. Hormonal therapy must be discontinued prior to study entry, excluding Luteinizing Hormone-Releasing Hormone (LHRH) analogue.
- Life expectancy greater than 6 months.
- Eastern Cooperative Oncology Group (ECOG) Performance Status performance status <2
Patients must have normal organ and marrow function as defined below:
- leukocytes ≥ 3,000/μL
- absolute neutrophil count ≥ 1,000/μL
- platelets ≥ 100,000/μL
- Haemoglobin ≥ 10 g/dl
- total bilirubin within normal institutional limits
- Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ≤ 2 X institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance ≥ 60 mL/min/1.73 m for patients with creatinine levels above institutional normal
- Geographically accessible for follow up.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Previous metronomic chemotherapy for advanced disease with capecitabine, cyclophosphamide and vinorelbine
- Patients defined as "refractory" to capecitabine, cyclophosphamide and vinorelbine (Progression Disease or Stable Disease < 6 months).
- Presence of symptomatic cerebral or leptomeningeal involvement.
- Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Malabsorption syndrome or disease affecting significantly gastrointestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine
- Concurrent treatment with any other anti-cancer therapy except LHRH analogue.
- Patients with pre-existing motor or sensory peripheral neuropathy grade 2 according to NCI criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metronomic VEX
Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
|
Metronomic Vinorelbine 40 mg orally thrice a week
Other Names:
Metronomic Capecitabine 500 mg, thrice daily
Other Names:
Metronomic Cyclophosphamide 50 mg daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to progression (TTP)
Time Frame: 28 days
|
the time between the first study dose administration and the date of progression of the disease or cancer-related death, whichever occurs first
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marco Colleoni, MD, European Institute of Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Cyclophosphamide
- Capecitabine
- Vinorelbine
Other Study ID Numbers
- IEO S582/111 RE324/2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Breast Cancer
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
Royal Marsden NHS Foundation TrustPfizer; Hoffmann-La RocheRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast CancerUnited Kingdom
-
NBE-Therapeutics AGCmed Clinical ServicesTerminatedTriple Negative Breast Cancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
Clinical Trials on Vinorelbine
-
Henan Cancer HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingBreast Cancer | Breast Diseases | HER2-positive Breast Cancer | Vinorelbine | PyrotinibChina
-
QLT Inc.TerminatedStage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
-
Merck KGaA, Darmstadt, GermanyCompletedNon Small Cell Lung Cancer (NSCLC)Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
-
Southern Europe New Drug OrganizationPierre Fabre Laboratories; AgennixUnknown
-
University of AarhusPierre Fabre LaboratoriesCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Taiwan Liposome CompanyCompletedCancerUnited States, Taiwan
-
Guangdong Association of Clinical TrialsTerminatedLung Neoplasm MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownBreast Cancer | Brain MetastasesChina